Abdominal obesity phenotypes and risk of cardiovascular disease in a decade of follow-up: The Tehran Lipid and Glucose Study

Atherosclerosis

Volumn 238, Issue 2, 2015, Pages 256-263

  Keihani, Sorena ^a   Hosseinpanah, Farhad ^a   Barzin, Maryam ^a   Serahati, Sara ^a   Doustmohamadian, Soraya ^b   Azizi, Fereidoun ^b  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Abdominal obesity; Cardiovascular disease; Metabolic syndrome; Metabolically healthy obesity

Indexed keywords

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; EDUCATIONAL STATUS; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; INSULIN RESISTANCE; IRAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PHYSICAL ACTIVITY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; SURVIVAL RATE; WAIST CIRCUMFERENCE; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; COMPARATIVE STUDY; GLUCOSE BLOOD LEVEL; HEALTH STATUS; INCIDENCE; METABOLISM; MIDDLE AGED; OBESITY, ABDOMINAL; PROGNOSIS; RISK FACTOR; TIME;

BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; LIPID;

ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS; HUMANS; INCIDENCE; INSULIN RESISTANCE; IRAN; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, ABDOMINAL; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; WAIST CIRCUMFERENCE;

EID: 84921364685     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.12.008     Document Type: Article

References (35)

1. Meigs J.B., Wilson P.W., Fox C.S., Vasan R.S., Nathan D.M., Sullivan L.M., D'Agostino R.B. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J.Clin. Endocrinol. Metabol. 2006, 91:2906-2912.
2. Appleton S.L., Seaborn C.J., Visvanathan R., Hill C.L., Gill T.K., Taylor A.W., Adams R.J. Diabetes and cardiovascular disease outcomes in the metabolically healthy obese phenotype: a cohort study. Diabetes care 2013, 36:2388-2394.
3. Karelis A.D., St-Pierre D.H., Conus F., Rabasa-Lhoret R., Poehlman E.T. Metabolic and body composition factors in subgroups of obesity: what do we know?. J.Clin. Endocrinol. Metabol. 2004, 89:2569-2575.
4. Kramer C.K., Zinman B., Retnakaran R. Are metabolically healthy overweight and obesity benign conditions?: a systematic review and meta-analysis. Ann. Intern. Med. 2013, 159:758-769.
5. Bluher M. Are there still healthy obese patients?. Curr. Opin. Endocrinol. Diabet. Obes. 2012, 19:341-346.
6. Ortega F.B., Lee D.C., Katzmarzyk P.T., Ruiz J.R., Sui X., Church T.S., Blair S.N. The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. Eur. Heart J. 2013, 34:389-397.
7. Arnlov J., Ingelsson E., Sundstrom J., Lind L. Impact of body mass index and the metabolic syndrome on the risk of cardiovascular disease and death in middle-aged men. Circulation 2010, 121:230-236.
8. Ogorodnikova A.D., Kim M., McGinn A.P., Muntner P., Khan U., Wildman R.P. Incident cardiovascular disease events in metabolically benign obese individuals. Obes. (Silver Spring) 2012, 20:651-659.
9. Thomsen M., Nordestgaard B.G. Myocardial infarction and ischemic heart disease in overweight and obesity with and without metabolic syndrome. JAMA Intern. Med. 2014, 174:15-22.
10. Hinnouho G.M., Czernichow S., Dugravot A., Nabi H., Brunner E.J., Kivimaki M., Singh-Manoux A. Metabolically healthy obesity and the risk of cardiovascular disease and type 2 diabetes: the Whitehall II cohort study. Eur. heart J. 2014.
11. van der A D.L., Nooyens A.C., van Duijnhoven F.J., Verschuren W.M., Boer J.M. All-cause mortality risk of metabolically healthy abdominal obese individuals: the EPIC-MORGEN study. Obes. (Silver Spring) 2014, 22:557-564.
12. Hamer M., Stamatakis E. Metabolically healthy obesity and risk of all-cause and cardiovascular disease mortality. J.Clin. Endocrinol. Metabol. 2012, 97:2482-2488.
13. Klein S., Allison D.B., Heymsfield S.B., Kelley D.E., Leibel R.L., Nonas C., Kahn R. Waist circumference and cardiometabolic risk: a consensus statement from shaping America's health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes care 2007, 30:1647-1652.
14. Carmienke S., Freitag M.H., Pischon T., Schlattmann P., Fankhaenel T., Goebel H., Gensichen J. General and abdominal obesity parameters and their combination in relation to mortality: a systematic review and meta-regression analysis. Eur. J. Clin. Nutr. 2013, 67:573-585.
15. Leitzmann M.F., Moore S.C., Koster A., Harris T.B., Park Y., Hollenbeck A., Schatzkin A. Waist circumference as compared with body-mass index in predicting mortality from specific causes. PloS One 2011, 6:e18582.
16. Despres J.P. Health consequences of visceral obesity. Ann. Med. 2001, 33:534-541.
17. Azizi F., Ghanbarian A., Momenan A.A., Hadaegh F., Mirmiran P., Hedayati M., Mehrabi Y., Zahedi-Asl S. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials 2009, 10:5.
18. Alberti K.G., Eckel R.H., Grundy S.M., Zimmet P.Z., Cleeman J.I., Donato K.A., Fruchart J.C., James W.P., Loria C.M., Smith S.C. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task force on Epidemiology and prevention; national heart, Lung, and blood Institute; American Heart Association; World Heart Federation; International atherosclerosis Society; and International Association for the study of obesity. Circulation 2009, 120:1640-1645.
19. Delavari A., Forouzanfar M.H., Alikhani S., Sharifian A., Kelishadi R. First nationwide study of the prevalence of the metabolic syndrome and optimal cutoff points of waist circumference in the Middle East: the national survey of risk factors for noncommunicable diseases of Iran. Diabetes care 2009, 32:1092-1097.
20. Hosseinpanah F., Borzooei S., Barzin M., Farshadi M., Sarvghadi F., Azizi F. Diagnostic values of metabolic syndrome definitions for detection of insulin resistance: Tehran Lipid and Glucose Study (TLGS). Arch. Iran. Med. 2012, 15:606-610.
21. Hadaegh F., Harati H., Ghanbarian A., Azizi F. Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study. Eur. J. Cardiovasc. Prev. Rehabil.: Off. J. Eur. Soc. Cardiol. Work. Groups Epidemiol. Prev. Cardiac Rehabil. Exerc. Physiol. 2006, 13:571-577.
22. Ainsworth B.E., Jacobs D.R., Leon A.S. Validity and reliability of self-reported physical activity status: the Lipid Research Clinics questionnaire. Med. Sci. Sports Exerc. 1993, 25:92-98.
23. Primeau V., Coderre L., Karelis A.D., Brochu M., Lavoie M.E., Messier V., Sladek R., Rabasa-Lhoret R. Characterizing the profile of obese patients who are metabolically healthy. Int. J. Obes. (Lond.) 2011, 35:971-981.
24. Pataky Z., Makoundou V., Nilsson P., Gabriel R.S., Lalic K., Muscelli E., Casolaro A., Golay A., Bobbioni-Harsch E. Metabolic normality in overweight and obese subjects. Which parameters? Which risks?. Int. J. Obes. (Lond.) 2011, 35:1208-1215.
25. Marini M.A., Succurro E., Frontoni S., Hribal M.L., Andreozzi F., Lauro R., Perticone F., Sesti G. Metabolically healthy but obese women have an intermediate cardiovascular risk profile between healthy nonobese women and obese insulin-resistant women. Diabetes Care 2007, 30:2145-2147.
26. Manu P., Ionescu-Tirgoviste C., Tsang J., Napolitano B.A., Lesser M.L., Correll C.U. Dysmetabolic signals in "metabolically healthy" obesity. Obes. Res. Clin. Pract. 2012, 6:e9-e20.
27. Kip K.E., Marroquin O.C., Kelley D.E., Johnson B.D., Kelsey S.F., Shaw L.J., Rogers W.J., Reis S.E. Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. Circulation 2004, 109:706-713.
28. Hosseinpanah F., Barzin M., Sheikholeslami F., Azizi F. Effect of different obesity phenotypes on cardiovascular events in Tehran Lipid and Glucose Study (TLGS). Am. J. Cardiol. 2011, 107:412-416.
29. Aung K., Lorenzo C., Hinojosa M.A., Haffner S.M. Risk of developing diabetes and cardiovascular disease in metabolically unhealthy normal-weight and metabolically healthy obese individuals. J.Clin. Endocrinol. Metabol. 2014, 99:462-468.
30. Bobbioni-Harsch E., Pataky Z., Makoundou V., Laville M., Disse E., Anderwald C., Konrad T., Golay A. From metabolic normality to cardiometabolic risk factors in subjects with obesity. Obes. (Silver Spring) 2012, 20:2063-2069.
31. Eshtiaghi R., Keihani S., Hosseinpanah F., Barzin M., Azizi F. Natural course of metabolically healthy abdominal obese adults after 10 years of follow-up: Tehran Lipid and Glucose Study. Int. J. Obes. (Lond.) 2014.
32. den Engelsen C., Gorter K.J., Salome P.L., Rutten G.E. Development of metabolic syndrome components in adults with a healthy obese phenotype: a 3-year follow-up. Obes. (Silver Spring) 2013, 21:1025-1030.
33. Soriguer F., Gutierrez-Repiso C., Rubio-Martin E., Garcia-Fuentes E., Almaraz M.C., Colomo N., Esteva de Antonio I., de Adana M.S., Chaves F.J., Morcillo S., Valdes S., Rojo-Martinez G. Metabolically healthy but obese, a matter of time? Findings from the prospective Pizarra study. J.Clin. Endocrinol. Metabol. 2013, 98:2318-2325.
34. Hosseinpanah F., Asghari G., Barzin M., Golkashani H.A., Azizi F. Prognostic impact of different definitions of metabolic syndrome in predicting cardiovascular events in a cohort of non-diabetic Tehranian adults. Int. J. Cardiol. 2013, 168:369-374.
35. Chang Y., Kim B.K., Yun K.E., Cho J., Zhang Y., Rampal S., Zhao D., Jung H.S., Choi Y., Ahn J., Lima J.A., Shin H., Guallar E., Ryu S. Metabolically-healthy obesity and coronary artery calcification. J.Am. Coll. Cardiol. 2014, 63:2679-2686.